Loading
RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.
Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signalling.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Gemcitabine. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.00, clinical 0.99).
In plain words · RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.
RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.
Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.
No product in this corpus aims at RRM2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA lists RRM2 among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA RRM2: RNA tissue enhanced (bone marrow 42 nTPM, lymphoid tissue 54 nTPM); no normal tissue stained high. Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Leukaemia, Breast cancer (all types), Lymphoma, Pancreatic ductal adenocarcinoma, Ovarian cancer, Myeloid neoplasms); Open Targets associates it with 11 specific cancer types at or above 0.5 (non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia, melanoma, exocrine pancreatic carcinoma, ovarian carcinoma, breast carcinoma and more). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas RRM2 tissue; Open Targets ENSG00000171848 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Pavloff et al, DNA Seq, 1992, "Sequence analysis of the large and small subunits of human ribonucleotide reductase". Source.
Sources: HGNC HGNC:10452 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P31350 (protein name, function text, keywords and locations (REST API)); CIViC gene RRM2 (1 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Cancer (GraphQL API, CC0)); Open Targets ENSG00000171848 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.62, ovarian cancer 0.59, melanoma 0.58, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.60 (GraphQL API, CC0))
Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signalling. Location: Cytoplasm; Nucleus (UniProt). Locus 2p25.1 (HGNC).
RNA: tissue enhanced (bone marrow 42 nTPM, lymphoid tissue 54 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Appendix, Colon, Duodenum, Rectum, Small intestine.
No cancer stained high; medium in colorectal cancer, liver cancer, lymphoma, stomach cancer.
HPA RRM2 tissue · HPA RRM2 pathology · HPA protein class: Essential proteins, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RRM2" OR ABSTRACT:"RRM2" OR TITLE:"ribonucleotide reductase regulatory subunit M2" OR ABSTRACT:"ribonucleotide reductase regulatory subunit M2" OR TITLE:"Ribonucleoside-diphosphate reductase subunit M2" OR ABSTRACT:"Ribonucleoside-diphosphate reductase subunit M2" OR TITLE:"FLJ25102" OR ABSTRACT:"FLJ25102" OR TITLE:"C2orf48" OR ABSTRACT:"C2orf48") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RRM2, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.